Treatment of chronic kidney transplant rejection with prostacyclin - reduction of platelet deposition in the transplant; prolongation of platelet survival and improvement of transplant function.
8 patients with chronic kidney transplant rejection were treated intravenously with prostacyclin during 5 days. This treatment seemed to have a beneficial effect as measured by platelet deposition in the transplant and prolongation of platelet survival. In the majority of cases the transplant function improved. A longer duration of this therapeutic effect could be a new way for the long-term treatment of chronic kidney transplant rejection.
D000328:Adult; D001792:Blood Platelets / Q000187:drug effects*; D002470:Cell Survival / Q000187:drug effects; D011464:Epoprostenol / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006084:Graft Rejection / Q000187:drug effects*; D006801:Humans; D007263:Infusions, Parenteral; D007668:Kidney / Q000098:blood supply; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D011453:Prostaglandins / Q000627:therapeutic use*
D011453:Prostaglandins; D011464:Epoprostenol